Skip to main content
Top
Published in: Obesity Surgery 11/2016

01-11-2016 | Original Contributions

Influence of Roux-en-Y Gastric Bypass on the Hepatocellular Function and Bile Flow of Obese Patients Assessed by Scintigraphy with DISIDA

Authors: Wilson Salgado Júnior, Carlos Augusto de Mattos Donadelli, José Sebastião dos Santos, Carla Barbosa Nonino

Published in: Obesity Surgery | Issue 11/2016

Login to get access

Abstract

Background

Obesity is associated with nonalcoholic fatty liver disease (NAFLD), which is improved by bariatric surgery. Hepatobiliary scintigraphy with 99m.-Tc diisopropylacetanilido iminodiacetic acid (99mTc-DISIDA) has proved to be highly effective for the assessment of bile flow, representing an indirect measurement of hepatocyte and cholangiocyte function. The objective of this study was to assess the effects of Roux-en-Y gastric bypass (RYGB) on bile flow in obese subjects by hepatobiliary scintigraphy. This study was conducted in a public university hospital in Brazil.

Methods

Twenty obese patients and five nonobese patients (with no hepatic or biliary disease) were studied. The obese patients were submitted to anthropometric evaluation and biochemical exams when they arrived at the service, during the immediate preoperative period and 3, 6, and 12 months after surgery. They were also submitted to abdominal ultrasound and hepatobiliary scintigraphy with 99mTc-DISIDA during the preoperative period and 12 months after RYGB. Tmax (time of maximum marker uptake) and T1/2 (half time between peak uptake and disappearance of the marker) were determined and compared between obese patients and controls, before and after surgery. The results were compared to those obtained with an intraoperative liver biopsy.

Results

A weight loss of 12.2 ± 4.3 % was observed during preparation for surgery, and a loss of 30.4 ± 5.6 % was observed 1 year after RYGB. Ultrasound hepatic analysis revealed some degree of NAFLD in the operated patients. Obese patients showed a prolonged T1/2 compared to control, with a reduction to normal levels after RYGB.

Conclusions

We concluded that NAFLD compromises bile excretion, a process that can be reversed by treatment with RYGB.
Literature
1.
go back to reference Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefPubMed Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefPubMed
2.
go back to reference Suter M, Donadini A, Romy S, et al. Laparoscopic Roux-en-Y gastric bypass: significant long-term weight loss, improvement of obesity-related comorbidities and quality of life. Ann Surg. 2011;254:267–73.CrossRefPubMed Suter M, Donadini A, Romy S, et al. Laparoscopic Roux-en-Y gastric bypass: significant long-term weight loss, improvement of obesity-related comorbidities and quality of life. Ann Surg. 2011;254:267–73.CrossRefPubMed
3.
go back to reference Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–8.CrossRefPubMed Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–8.CrossRefPubMed
4.
go back to reference Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol. 2007;23:193–8.CrossRefPubMed Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol. 2007;23:193–8.CrossRefPubMed
5.
go back to reference Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112.CrossRefPubMed Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112.CrossRefPubMed
7.
go back to reference Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222–6.CrossRefPubMed Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222–6.CrossRefPubMed
8.
go back to reference Furuya Jr CK, de Oliveira CP, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol. 2007;22(4):510–4.CrossRefPubMed Furuya Jr CK, de Oliveira CP, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol. 2007;22(4):510–4.CrossRefPubMed
9.
go back to reference Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396–402.CrossRefPubMed Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396–402.CrossRefPubMed
10.
go back to reference Moretto M, Kupski C, da Silva VD, et al. Effect of bariatric surgery on liver fibrosis. Obes Surg. 2012;22(7):1044–9.CrossRefPubMed Moretto M, Kupski C, da Silva VD, et al. Effect of bariatric surgery on liver fibrosis. Obes Surg. 2012;22(7):1044–9.CrossRefPubMed
11.
go back to reference Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33(5):525–40.CrossRefPubMed Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33(5):525–40.CrossRefPubMed
12.
go back to reference Mueller M, Kratzer W, Oeztuerk S, et al. Percutaneous ultrasonographically guided liver punctures: an analysis of 1961 patients over a period of ten years. BMC Gastroenterol. 2012;12:173.CrossRefPubMedPubMedCentral Mueller M, Kratzer W, Oeztuerk S, et al. Percutaneous ultrasonographically guided liver punctures: an analysis of 1961 patients over a period of ten years. BMC Gastroenterol. 2012;12:173.CrossRefPubMedPubMedCentral
13.
go back to reference Masuda K, Ono M, Fukumoto M, et al. Usefulness of technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease. Hepatol Res. 2012;42(3):273–9.CrossRefPubMed Masuda K, Ono M, Fukumoto M, et al. Usefulness of technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease. Hepatol Res. 2012;42(3):273–9.CrossRefPubMed
14.
go back to reference Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefPubMed Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefPubMed
15.
go back to reference Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr. 2006;84(2):304–11.PubMed Colles SL, Dixon JB, Marks P, et al. Preoperative weight loss with a very-low-energy diet: quantitation of changes in liver and abdominal fat by serial imaging. Am J Clin Nutr. 2006;84(2):304–11.PubMed
16.
go back to reference Tarnoff M, Kaplan LM, Shikora S. An evidence-based assessment of preoperative weight loss in bariatric surgery. Obes Surg. 2008;18(9):1059–61.CrossRefPubMed Tarnoff M, Kaplan LM, Shikora S. An evidence-based assessment of preoperative weight loss in bariatric surgery. Obes Surg. 2008;18(9):1059–61.CrossRefPubMed
17.
go back to reference Shimada M, Hashimoto E, Kaneda H, et al. Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res. 2002;24(4):429–38.CrossRefPubMed Shimada M, Hashimoto E, Kaneda H, et al. Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res. 2002;24(4):429–38.CrossRefPubMed
19.
go back to reference Dyson JK, Anstee QM, Mcpherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211–8.CrossRefPubMed Dyson JK, Anstee QM, Mcpherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211–8.CrossRefPubMed
20.
go back to reference Ma H, Patti ME. Bile acids, obesity and the metabolic syndrome. Best Practice & Research Clinical Gastroenterology. 2014;28:533–44.CrossRef Ma H, Patti ME. Bile acids, obesity and the metabolic syndrome. Best Practice & Research Clinical Gastroenterology. 2014;28:533–44.CrossRef
21.
go back to reference Penney NC, Kinross J, Newton RC, et al. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int J Obes. 2015;39:1565–74.CrossRef Penney NC, Kinross J, Newton RC, et al. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. Int J Obes. 2015;39:1565–74.CrossRef
22.
go back to reference Glicksman C, Pournaras DJ, Wright M, et al. Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem. 2010;47:482–4.CrossRefPubMed Glicksman C, Pournaras DJ, Wright M, et al. Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem. 2010;47:482–4.CrossRefPubMed
23.
go back to reference Okuda H, Nunes R, Vallabhajosula S, et al. Studies of the hepatocellular uptake of the hepatobiliary scintiscanning agent 99mTc-DISIDA. J Hepatol. 1986;3(2):251–9.CrossRefPubMed Okuda H, Nunes R, Vallabhajosula S, et al. Studies of the hepatocellular uptake of the hepatobiliary scintiscanning agent 99mTc-DISIDA. J Hepatol. 1986;3(2):251–9.CrossRefPubMed
24.
go back to reference Kamisaka K, Gatmaitan Z, Moore CL, et al. Ligandin reverses bilirubin inhibition of liver mitochondrial respiration in vitro. Pediatr Res. 1975;9(12):903–5.CrossRefPubMed Kamisaka K, Gatmaitan Z, Moore CL, et al. Ligandin reverses bilirubin inhibition of liver mitochondrial respiration in vitro. Pediatr Res. 1975;9(12):903–5.CrossRefPubMed
25.
go back to reference Pizarro M, Balasubramaniyan N, Solís N, et al. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut. 2004;53(12):1837–43.CrossRefPubMedPubMedCentral Pizarro M, Balasubramaniyan N, Solís N, et al. Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function. Gut. 2004;53(12):1837–43.CrossRefPubMedPubMedCentral
27.
go back to reference Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–46.CrossRefPubMed Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–46.CrossRefPubMed
Metadata
Title
Influence of Roux-en-Y Gastric Bypass on the Hepatocellular Function and Bile Flow of Obese Patients Assessed by Scintigraphy with DISIDA
Authors
Wilson Salgado Júnior
Carlos Augusto de Mattos Donadelli
José Sebastião dos Santos
Carla Barbosa Nonino
Publication date
01-11-2016
Publisher
Springer US
Published in
Obesity Surgery / Issue 11/2016
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-016-2176-2

Other articles of this Issue 11/2016

Obesity Surgery 11/2016 Go to the issue